Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices 29127

Enhancement Award; 93.936, NIH Acquired (HHS Reference No. E–619–2013–0–US– within fifteen (15) days from the date of Immunodeficiency Syndrome Research Loan 01); this published notice, the National Repayment Program; 93.187, Undergraduate 2. PCT Application No. PCT/US2014/ Institute of Dental and Craniofacial Scholarship Program for Individuals from 058613, filed October 1, 2014 and Research receives written evidence and Disadvantaged Backgrounds, National entitled ‘‘Methods of Modulating Institutes of Health, HHS) argument that establishes that the grant Erythropoiesis with Arginine of the license would not be consistent Dated: June 19, 2018. 1B Molecules’’ with the requirements of 35 U.S.C. 209 Natasha M. Copeland, (HHS Reference No. E–619–2013–0– and 37 CFR part 404. PCT–02); In response to this Notice, the public Program Analyst, Office of Federal Advisory 3. U.S. Patent Application No. 15/ Committee Policy. may file comments or objections. 022,531, filed March 16, 2016 and [FR Doc. 2018–13419 Filed 6–21–18; 8:45 am] Comments and objections, other than entitled ‘‘Methods of Modulating those in the form of a license BILLING CODE 4140–01–P Erythropoiesis with Arginine application, will not be treated 1B Molecules’’ confidentially, and may be made (HHS Reference No. E–619–2013–0–US– DEPARTMENT OF HEALTH AND publicly available. 03); HUMAN SERVICES License applications submitted in The patent rights in these inventions response to this Notice will be National Institutes of Health have been assigned and/or exclusively presumed to contain business licensed to the government of the confidential information and any release Prospective Grant of an Exclusive United States of America. of information in these license Patent License: Methods of Modulating The prospective exclusive license applications will be made only as Erythropoiesis With Arginine territory may be the United States and required and upon a request under the Molecules the field of use may be limited to ‘‘Use Freedom of Information Act, 5 U.S.C. of arginine vasopressin receptor 1B 552. AGENCY: National Institutes of Health, to treat anemia caused by (i) HHS. chronic renal failure on dialysis, (ii) Dated: June 19, 2018. David W. Bradley, ACTION: Notice. receiving myelosuppressive chemotherapy, or (iii) lacking Director, Office of Technology Transfer and SUMMARY: The National Institute of antidiuretic hormone.’’ Innovation Access, National Institute of Dental and Craniofacial Research, an The subject technology is a method of Dental and Craniofacial Research, National institute of the National Institutes of using arginine vasopressin receptor 1B Institutes of Health. Health, Department of Health and (AVPR1B) agonists to increase the [FR Doc. 2018–13443 Filed 6–21–18; 8:45 am] Human Services, is contemplating the number of red blood cells to treat BILLING CODE 4140–01–P grant of an Exclusive Patent License to anemia. The inventors discovered that practice the inventions embodied in the hematopoietic stem cells express Patent Applications listed in the AVPR1B receptor, and these receptors DEPARTMENT OF HEALTH AND Supplementary Information section of play a key role in promoting HUMAN SERVICES hematopoietic stem and progenitor cell this notice to ERYTHRYx Therapeutics, National Institutes of Health located in Los Angeles, California. proliferation. The number of red blood DATES: Only written comments and/or cells and their precursors significantly Government-Owned Inventions; applications for a license which are increased on day 2 following Availability for Licensing received by the Office of Technology vasopressin administration, an onset AGENCY: National Institutes of Health, Transfer and Innovation Access, time much faster than erythropoietin HHS. National Institute of Dental and (EPO), which is commonly used to Craniofacial Research on or before July stimulate red blood cell production for ACTION: Notice. 9, 2018 will be considered. anemia treatment. EPO takes about a week to manifest its clinical effects. The SUMMARY: The invention listed below is ADDRESSES: Requests for copies of the AVPR1B agonists can be used to owned by an agency of the U.S. patent application, inquiries, and jumpstart the hematopoietic system and Government and is available for comments relating to the contemplated erythropoietin can be used to sustain licensing to achieve expeditious an Exclusive Patent License should be the effect. commercialization of results of directed to: Yun Mei, Technology The subject technology is a federally-funded research and Transfer and Patent Specialist, Office of repurposing of an existing drug, development. Foreign patent Technology Transfer and Innovation vasopressin, an AVPR1B , also applications are filed on selected Access, National Institute of Dental and called antidiuretic hormone. It is a nine- inventions to extend market coverage Craniofacial Research, National amino acid peptide secreted from the for companies and may also be available Institutes of Health, BLDG 1 DEM, posterior pituitary and used to treat for licensing. RM667, 6701 Democracy Blvd., patients with central diabetes insipidus, FOR FURTHER INFORMATION CONTACT: Dr. Bethesda, MD 20817; Telephone: (301) an uncommon disorder that causes an Barry Buchbinder, 240–627–3678; 827–4639; Facsimile: (301) 496–1005; imbalance of water in the body. This [email protected]. Licensing Email: [email protected]. imbalance leads to excretion of large information and copies of the U.S. SUPPLEMENTARY INFORMATION: amount of urine (polyuria) and intense patent application listed below may be thirst even after drinking fluids obtained by communicating with the Intellectual Property (polydipsia). indicated licensing contact at the 1. U.S. Provisional Patent Application This notice is made in accordance Technology Transfer and Intellectual No. 61/885,258, filed October 1, 2013 with 35 U.S.C. 209 and 37 CFR part 404. Property Office, National Institute of and entitled ‘‘Methods of Modulating The prospective exclusive license will Allergy and Infectious Diseases, 5601 Erythropoiesis with Arginine be royalty bearing, and the prospective Fishers Lane, Rockville, MD 20852; tel. Vasopressin Receptor 1B Molecules’’ exclusive license may be granted unless 301–496–2644. A signed Confidential

VerDate Sep<11>2014 17:16 Jun 21, 2018 Jkt 244001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1 daltland on DSKBBV9HB2PROD with NOTICES